Lumos Pharma, Inc.

Ilex Products, Inc.

Southwest Research Institute

Genzyme Corporation

Bioaffinity Technologies, Inc.

Heidelberg Pharma Ag

Oncoselect Therapeutics, LLC

Baylor College of Medicine

Tvardi Therapeutics, Inc.

William E Bauta

William R Cantrell, Jr

Dennis P Lovett

Jose Puente

Brian D Burke

Brian E Schulmeier

Vivienne I Rebel

Stephen Thomas Wellinghoff

Hong Dixon

Joseph A McDonough

Dieter Herrmann

Christian Lutz

Michael Wade Tidwell

David John Tweardy

Christoph Mueller

David J Elzi

Brigitte Heckl-Oestreicher

Kevin Fitzpatrick

Robert Voigt

Maria Zannes

Sofia De Achaval Wied

A double stranded RNA interference (RNAi) agent comprising at least one of (i) a first double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a CD320 gene wherein the first dsRNA comprises a sense strand and an antisense strand forming a duplex, (ii) a second dsRNA for inhibiting the expression of a LRP2 gene wherein the second dsRNA comprises a sense strand and an antisense strand forming a duplex, or (iii) a cocktail of (i) and (ii) and wherein the sense strand of the first dsRNA is at least substantially complementary to the antisense strand of the first dsRNA and the sense strand of the second dsRNA is at least substantially complementary to the antisense strand of the second dsRNA and the use of the RNAi agent as a pharmaceutical composition for the treatment of cancer in subjects in need of treatment.

Compositions and methods for treating cancer

Porphyrin compounds and compositions useful for treating cancer

The present disclosure relates to the preparation of polymorphic mixtures of Cepharanthine.2HCl. Mixtures of at least two polymorphic forms can be formed into a mobile liquid phase in organic/aqueous solvent mixtures along with enteric polymer that can be spray dried to produce solid particulate enteric formulations for medicinal drug-treatment applications.

Pharmaceutical salt forms of Cepharanthine and Tetrandrine

Provided herein is a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, using cynamide in the reaction. 

Synthesis of cyclocreatine and analogs thereof

Provided herein is a process and intermediates for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, using cyanamide in the reaction. 

The present invention relates to organophosphate-inhibited acetylcholinesterase (AChE) reactivators with central nervous system (CNS) bioavailability and their associated methods of preparation including their use for treatment of exposure to AChE inhibitors such as an organophosphate (OP) insecticides and nerve agents.

Reactivators of organophosphorous inhibited acetylcholinesterase

The present invention for the stereoselective preparation of 2-deoxy-&#x3b2;-D-adenine nucleosides wherein a blocked 2-deoxy-&#x3b1;-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative.

Process for preparing purine nucleosides

The subject of the present invention is specific lipidesters of halogenated nucleotides of the following formula wherein R, R, R, X and Y are defined as described herein and salts thereof, said compounds have anti-cancer properties; pharmaceutical compositions containing the compounds, a method of synthesizing the compounds, and a method of using the compounds for treating malignant tumors.

Nucleotide lipid ester derivatives

The present invention provides a process for the preparation of homophthlate esters useful in the preparation of homophthalic anhydride reactants.

Process for preparing homophthalate derivatives

The present invention provides for the preparation &bgr;-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy-&bgr;-D-adenine nucleosides wherein a blocked 2-deoxy-&agr;-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative. The forgoing aspects of the present invention are utilized in the preparation of a clofarabine composition wherein the ratio of &bgr; to &agr;-anomer is at least 99:1.

The present invention provides a process from preparing isocoumarin-3-yl derivatives comprising reacting a homophthalic anhydride derivative with a carbonyl compound, wherein the carbonyl group is substituted with an acyl activating group, in the presence of a reaction medium comprising a solvent and a base. The invention also encompasses a process for the preparation of homophthalate esters useful in the preparation of homophthalic anhydride reactants as well as an integrated process wherein the twp reactions are carried out sequentially to afford the desired isocoumarin derivative.

Growing community of inventors

San Antonio, TX, United States of America

William E Bauta